Eleusis acquires a ketamine therapy provider and announces a new R&D program.
Articles
MindMed Announces Successful Completion of Pre-IND Meeting with the FDA for Project Lucy
MindMed announces a successful pre-Investigational New Drug meeting with the FDA regarding its Project Lucy (LSD) research for anxiety.
MindMed Announces $50 Million Bought Deal Public Offering
MindMed continues to raise capital. This time issuing 11,364,000 units at CAD$4.40 for gross proceeds of CAD$50,001,600.
UK Approves Trials Testing DMT as Depression Treatment
The United Kingdom has approved trials by London-based Small Pharma for assessing the safety, and later efficacy, of N,N-dimethyltryptamine – or DMT – for depression, according to a Pharm Exec report. It is the world’s first clinical trial for studying DMT as a depression treatment.
Psychedelic Stocks Pump Up The Volume
Psychedelic stocks are hitting new highs -- and doing so on record trading volumes. Feeding frenzies.
MindMed Closes Upsized Financing of CAD $34.5m, Gross Proceeds Raised Since Company Founding Now Total CAD $121.4m (USD $94.8m)
MindMed's recent financing has closed after being upsized all the way to CAD$34.5 million.
Arizona Releases Draft Marijuana Regulations To Implement Legalization Vote
One month after Arizona voters overwhelmingly approved a ballot initiative to legalize marijuana for adult use, regulators have already put forward draft regulations to implement the program.
Magic Mushrooms Are Expanding Minds and Advancing an Emerging Field of Science
They’ve been credited in part for the musical and artistic revolutions of the late 1960s. According to some scientific opinions, they have potentially inspired early creativity in humans and our ancient ancestors.
Rotation Opportunity As Three Top Psychedelic Stocks Explode
Leading psychedelic stocks have gone ballistic in recent weeks. But where will investors find the NEXT multi-bagger opportunity?
Mind Cure (CSE: MCUR | OTC: MCURF) Moves into Psychedelic Assisted Therapy with British Columbia Location Offering Ketamine and Psilocybin Therapy
The company is set to open a therapeutic health and training center in Kelowna, British Columbia in May of 2021
Entheon Biomedical Announces DMT Drug Supply Agreement with Psygen Labs Inc. Completion of Initial DMT Research Drug Batch and Exercise of Warrants
Entheon has secured a supply of DMT for delivery to its drug research center (CHDR) in the Netherlands.
Mind Cure Announces its Research Program with Psychedelic Compounds
Mind Cure's initial R&D focus will be on psilocybin, ketamine and ibogaine. Researching both pain and mental health applications for psychedelics.
Mydecine Innovations Group to Make First Commercial Export of Legal Psilocybin Mushrooms
Mydecine completes its first commercial harvest of 20 kilograms of psilocybin mushrooms.
Champignon Brands Appoints Christopher Hobbs as Interim Chief Financial Officer
Champignon Brands names an interim CFO after Stephen Brohman resigns.
Canada Will Let Health Care Professionals Legally Use Psychedelic Mushrooms, Health Minister Says
Canada will allow a handful of health care professionals to possess and consume psilocybin mushrooms in order to better treat the growing number of patients now permitted to use the psychedelic drug, the country’s top health official revealed in a recent interview.